Further development of a liquid chromatography-high-resolution mass spectrometry/mass spectrometry-based strategy for analyzing eight biomarkers in human urine indicating toxic mushroom or Ricinus communis ingestions.
HILIC-HRMS/MS
matrix variability
mushroom intoxication
mushroom toxins
urinary biomarker
Journal
Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
revised:
31
05
2021
received:
07
05
2021
accepted:
01
06
2021
pubmed:
4
6
2021
medline:
22
1
2022
entrez:
3
6
2021
Statut:
ppublish
Résumé
Recently, we presented a strategy for analysis of eight biomarkers in human urine to verify toxic mushroom or Ricinus communis ingestions. However, screening for the full panel is not always necessary. Thus, we aimed to develop a strategy to reduce analysis time and by focusing on two sets of analytes. One set (A) for biomarkers of late-onset syndromes, such as phalloides syndrome or the syndrome after castor bean intake. Another set (B) for biomarkers of early-onset syndromes, such as pantherine-muscaria syndrome and muscarine syndrome. Both analyses should be based on hydrophilic-interaction liquid chromatography coupled with high-resolution mass spectrometry (MS)/MS (HILIC-HRMS/MS). For A, urine samples were prepared by liquid-liquid extraction using dichloromethane and subsequent solid-phase extraction of the aqueous supernatant. For B urine was precipitated using acetonitrile. Method A was validated for ricinine and α- and β-amanitin and method B for muscarine, muscimol, and ibotenic acid according to the specifications for qualitative analytical methods. In addition, robustness of recovery and normalized matrix factors to matrix variability measured by urinary creatinine was tested. Moreover, applicability was tested using 10 urine samples from patients after suspected mushroom intoxication. The analytes α- and β-amanitin, muscarine, muscimol, and ibotenic acid could be successfully identified. Finally, psilocin-O-glucuronide could be identified in two samples and unambiguously distinguished from bufotenine-O-glucuronide via their MS
Substances chimiques
Biomarkers
0
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1603-1613Informations de copyright
© 2021 The Authors. Drug Testing and Analysis published by John Wiley & Sons Ltd.
Références
Schenk-Jaeger KM, Rauber-Luthy C, Bodmer M, Kupferschmidt H, Kullak-Ublick GA, Ceschi A. Mushroom poisoning: a study on circumstances of exposure and patterns of toxicity. Eur J Intern Med. 2012;23(4):e85-e91. https://doi.org/10.1016/j.ejim.2012.03.014
Troiano G, Firmi AM, Adorni C, et al. Wild mushrooms poisoning: a public health challenge. Eur J Public Health. 2020;30(Supplement_5). https://doi.org/10.1093/eurpub/ckaa166.189
Govorushko S, Rezaee R, Dumanov J, Tsatsakis A. Poisoning associated with the use of mushrooms: a review of the global pattern and main characteristics. Food Chem Toxicol. 2019;128:267-279. https://doi.org/10.1016/j.fct.2019.04.016
Flament E, Guitton J, Gaulier JM, Gaillard Y. Human poisoning from poisonous higher fungi: focus on analytical toxicology and case reports in forensic toxicology. Pharmaceuticals (Basel). 2020;13(12):454. https://doi.org/10.3390/ph13120454
Wennig R, Eyer F, Schaper A, Zilker T, Andresen-Streichert H. Mushroom poisoning. Dtsch Arztebl Int. 2020;117(42):701-708. https://doi.org/10.3238/arztebl.2020.0701
White J, Weinstein SA, De Haro L, et al. Mushroom poisoning: a proposed new clinical classification. Toxicon. 2019;157:53-65. https://doi.org/10.1016/j.toxicon.2018.11.007
Benjamin DR. Mushroom poisoning in infants and children: the Amanita pantherina/muscaria group. J Toxicol Clin Toxicol. 1992;30(1):13-22. https://doi.org/10.3109/15563659208994442
Grabhorn E, Nielsen D, Hillebrand G, et al. Successful outcome of severe Amanita phalloides poisoning in children. Pediatr Transplant. 2013;17(6):550-555. https://doi.org/10.1111/petr.12108
Karlson-Stiber C, Persson H. Cytotoxic fungi-an overview. Toxicon. 2003;42(4):339-349. https://doi.org/10.1016/s0041-0101(03)00238-1
Thornton SL, Darracq M, Lo J, Cantrell FL. Castor bean seed ingestions: a state-wide poison control system's experience. Clin Toxicol (Phila). 2014;52(4):265-268. https://doi.org/10.3109/15563650.2014.892124
Worbs S, Kohler K, Pauly D, et al. Ricinus communis intoxications in human and veterinary medicine-a summary of real cases. Toxins (Basel). 2011;3(10):1332-1372. https://doi.org/10.3390/toxins3101332
Stebelska K. Fungal hallucinogens psilocin, ibotenic acid, and muscimol: analytical methods and biologic activities. Ther Drug Monit. 2013;35(4):420-442. https://doi.org/10.1097/FTD.0b013e31828741a5
Yockey A, King K. Use of psilocybin (“mushrooms”) among US adults: 2015-2018. J Psychedelic Studies. 2021;5(1):17-21. https://doi.org/10.1556/2054.2020.00159
Tullis P. How ecstasy and psilocybin are shaking up psychiatry. Nature. 2021;589(7843):506-509. https://doi.org/10.1038/d41586-021-00187-9
Vargas AS, Luis A, Barroso M, Gallardo E, Pereira L. Psilocybin as a new approach to treat depression and anxiety in the context of life-threatening diseases-a systematic review and meta-analysis of clinical trials. Biomedicine. 2020;8(9):331. https://doi.org/10.3390/biomedicines8090331
United Nations. Convention on Psychotropic Substances 1971. https://www.unodc.org/pdf/convention_1971_en.pdf. Accessed April 13, 2021.
Aday JS, Bloesch EK, Davoli CC. A year of expansion in psychedelic research, industry, and deregulation. Drug Sci Policy Law. 2019;2020(6):1-6. https://doi.org/10.1177/2050324520974484
Bambauer TP, Wagmann L, Maurer HH, Weber AA, Meyer MR. Development and application of a strategy for analyzing eight biomarkers in human urine to verify toxic mushroom or ricinus communis ingestions by means of hydrophilic interaction LC coupled to HRMS/MS. Talanta. 2020;213:120847. https://doi.org/10.1016/j.talanta.2020.120847
Weil AT, Davis W. Bufo alvarius: a potent hallucinogen of animal origin. J Ethnopharmacol. 1994;41(1-2):1-8. https://doi.org/10.1016/0378-8741(94)90051-5
Lyttle T, Goldstein D, Gartz J. Bufo toads and bufotenine: fact and fiction surrounding an alleged psychedelic. J Psychoactive Drugs. 1996;28(3):267-290. https://doi.org/10.1080/02791072.1996.10472488
Barker SA, McIlhenny EH, Strassman R. A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955-2010. Drug Test Anal. 2012;4(7-8):617-635. https://doi.org/10.1002/dta.422
Dean JG. Indolethylamine-N-methyltransferase polymorphisms: genetic and biochemical approaches for study of endogenous N,N,-dimethyltryptamine. Front Neurosci. 2018;12:232. https://doi.org/10.3389/fnins.2018.00232
Martin R, Schürenkamp J, Gasse A, Pfeiffer H, Köhler H. Determination of psilocin, bufotenine, LSD and its metabolites in serum, plasma and urine by SPE-LC-MS/MS. Int J Leg Med. 2013;127(3):593-601. https://doi.org/10.1007/s00414-012-0796-1
Garcia J, Costa VM, Costa AE, et al. Co-ingestion of amatoxins and isoxazoles-containing mushrooms and successful treatment: a case report. Toxicon. 2015;103:55-59. https://doi.org/10.1016/j.toxicon.2015.06.012
Audi J, Belson M, Patel M, Schier J, Osterloh J. Ricin poisoning: a comprehensive review. JAMA. 2005;294(18):2342-2351. https://doi.org/10.1001/jama.294.18.2342
Beuhler MC. Overview of mushroom poisoning. In: Brent J, Burkhart K, Dargan P, et al., eds. Critical Care Toxicology: Diagnosis and Management of the Critically Poisoned Patient. 2nd ed. Springer; 2017:2103-2128. https://doi.org/10.1007/978-3-319-17900-1_120
Oss OT, Oeric ON. Psilocybin: Magic Mushroom Grower's Guide: A Handbook for Psilocybin Enthusiasts. 2nded. Quick American Archives; 1993.
Gambaro V, Roda G, Visconti GL, et al. DNA-based taxonomic identification of basidiospores in hallucinogenic mushrooms cultivated in “grow-kits” seized by the police: LC-UV quali-quantitative determination of psilocybin and psilocin. J Pharm Biomed Anal. 2016;125:427-432. https://doi.org/10.1016/j.jpba.2016.03.043
Martin R, Schürenkamp J, Pfeiffer H, Köhler H. A validated method for quantitation of psilocin in plasma by LC-MS/MS and study of stability. Int J Leg Med. 2012;126(6):845-849. https://doi.org/10.1007/s00414-011-0652-8
Martin R, Schürenkamp J, Pfeiffer H, Lehr M, Köhler H. Synthesis, hydrolysis and stability of psilocin glucuronide. Forensic Sci Int. 2014;237:1-6. https://doi.org/10.1016/j.forsciint.2014.01.006
Helfer AG, Michely JA, Weber AA, Meyer MR, Maurer HH. Orbitrap technology for comprehensive metabolite-based liquid chromatographic-high resolution-tandem mass spectrometric urine drug screening-exemplified for cardiovascular drugs. Anal Chim Acta. 2015;891:221-233. https://doi.org/10.1016/j.aca.2015.08.018
Wille SMR, Coucke W, De Baere T, Peters FT. Update of standard practices for new method validation in forensic toxicology. Curr Pharm des. 2017;23(36):5442-5454. https://doi.org/10.2174/1381612823666170714154444
European Medicines Agency. Guideline on bioanalytical method validation. EMEA/CHMP/EWP/192217/2009 Rev.1 Corr.2 2015 ed. London, UK: Committee for Medicinal Products for Human Use (CHMP); 2011.
Peters FT, Drummer OH, Musshoff F. Validation of new methods. Forensic Sci Int. 2007;165(2-3):216-224. https://doi.org/10.1016/j.forsciint.2006.05.021
Helfer AG, Michely JA, Weber AA, Meyer MR, Maurer HH. Liquid chromatography-high resolution-tandem mass spectrometry using Orbitrap technology for comprehensive screening to detect drugs and their metabolites in blood plasma. Anal Chim Acta. 2017;965:83-95. https://doi.org/10.1016/j.aca.2017.03.002
Ginterova P, Sokolova B, Ondra P, et al. Determination of mushroom toxins ibotenic acid, muscimol and muscarine by capillary electrophoresis coupled with electrospray tandem mass spectrometry. Talanta. 2014;125:242-247. https://doi.org/10.1016/j.talanta.2014.03.019
Maurer HH, Schmitt CJ, Weber AA, Kraemer T. Validated electrospray liquid chromatographic-mass spectrometric assay for the determination of the mushroom toxins alpha- and beta-amanitin in urine after immunoaffinity extraction. J Chromatogr B Biomed Sci Appl. 2000;748(1):125-135. https://doi.org/10.1016/S0378-4347(00)00270-X
Helfer AG, Meyer MR, Michely JA, Maurer HH. Direct analysis of the mushroom poisons alpha- and beta-amanitin in human urine using a novel on-line turbulent flow chromatography mode coupled to liquid chromatography-high resolution-mass spectrometry/mass spectrometry. J Chromatogr A. 2014;1325:92-98. https://doi.org/10.1016/j.chroma.2013.11.054
Stribrny J, Sokol M, Merova B, Ondra P. GC/MS determination of ibotenic acid and muscimol in the urine of patients intoxicated with Amanita pantherina. Int J Leg Med. 2012;126(4):519-524. https://doi.org/10.1007/s00414-011-0599-9
Grieshaber AF, Moore KA, Levine B. The detection of psilocin in human urine. J Forensic Sci. 2001;46(3):627-630. https://doi.org/10.1520/jfs15014j
Verougstraete N, Helsloot D, Deprez C, Heylen O, Casier I, Croes K. Lethal injection of a castor bean extract: ricinine quantification as a marker for ricin exposure using a validated LC-MS/MS method. J Anal Toxicol. 2019;43(3):e1-e5. https://doi.org/10.1093/jat/bky100
Abbott NL, Hill KL, Garrett A, Carter MD, Hamelin EI, Johnson RC. Detection of α-, β-, and γ-amanitin in urine by LC-MS/MS using 15N10-α-amanitin as the internal standard. Toxicon. 2018;152:71-77. https://doi.org/10.1016/j.toxicon.2018.07.025
Bambauer TP, Wagmann L, Weber AA, Meyer MR. Analysis of α- and β-amanitin in human plasma at subnanogram per milliliter levels by reversed phase ultra-high performance liquid chromatography coupled to Orbitrap mass spectrometry. Toxins (Basel). 2020;12(11):671. https://doi.org/10.3390/toxins12110671
Xu XM, Zhang JS, Huang BF, Han JL, Chen Q. Determination of ibotenic acid and muscimol in plasma by liquid chromatography-triple quadrupole mass spectrometry with bimolecular dansylation. J Chromatogr B Analyt Technol Biomed Life Sci. 2020;1146:122128. https://doi.org/10.1016/j.jchromb.2020.122128
Tomková J, Ondra P, Valka I. Simultaneous determination of mushroom toxins alpha-amanitin, beta-amanitin and muscarine in human urine by solid-phase extraction and ultra-high-performance liquid chromatography coupled with ultra-high-resolution TOF mass spectrometry. Forensic Sci Int. 2015;251:209-213. https://doi.org/10.1016/j.forsciint.2015.04.007
Sticht G, Käferstein H. Detection of psilocin in body fluids. Forensic Sci Int. 2000;113(1-3):403-407. https://doi.org/10.1016/s0379-0738(00)00213-9
Kamata T, Nishikawa M, Katagi M, Tsuchihashi H. Direct detection of serum psilocin glucuronide by LC/MS and LC/MS/MS: time-courses of total and free (unconjugated) psilocin concentrations in serum specimens of a “magic mushroom” user. Forensic Toxicol. 2006;24(1):36-40. https://doi.org/10.1007/s11419-006-0006-2
Zhang S, Zhao Y, Li H, et al. A simple and high-throughput analysis of amatoxins and phallotoxins in human plasma, serum and urine using UPLC-MS/MS combined with PRiME HLB μElution platform. Toxins. 2016;8(5):128. https://doi.org/10.3390/toxins8050128
Merova B, Ondra P, Stankova M, et al. Determination of muscarine in human urine by electrospray liquid chromatographic-mass spectrometric. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879(25):2549-2553. https://doi.org/10.1016/j.jchromb.2011.07.009
Wagner BD, Accurso FJ, Laguna TA. The applicability of urinary creatinine as a method of specimen normalization in the cystic fibrosis population. J Cyst Fibros. 2010;9(3):212-216. https://doi.org/10.1016/j.jcf.2010.02.004
Weihrauch M, Schulze B, Schaller KH. Creatinine as a reference parameter for the concentration of substances in urine [BAT value documentation, 1998]. In: Greim H, ed. The MAK-Collection for Occupational Health and Safety: Annual Thresholds and Classifications for the Workplace. Vol.2002. Wiley-VCH:36-44. https://doi.org/10.1002/3527600418.bb6027urie0003
Sauve JF, Levesque M, Huard M, et al. Creatinine and specific gravity normalization in biological monitoring of occupational exposures. J Occup Environ Hyg. 2015;12(2):123-129. https://doi.org/10.1080/15459624.2014.955179
Cone EJ, Caplan YH, Moser F, Robert T, Shelby MK, Black DL. Normalization of urinary drug concentrations with specific gravity and creatinine. J Anal Toxicol. 2009;33(1):1-7. https://doi.org/10.1093/jat/33.1.1
Waikar SS, Sabbisetti VS, Bonventre JV. Normalization of urinary biomarkers to creatinine during changes in glomerular filtration rate. Kidney Int. 2010;78(5):486-494. https://doi.org/10.1038/ki.2010.165
Mazzachi BC, Peake MJ, Ehrhardt V. Reference range and method comparison studies for enzymatic and Jaffe creatinine assays in plasma and serum and early morning urine. Clin Lab. 2000;46(1-2):53-55.